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ulti-resistant Enterobacteriaceae
. Turnidge
Women’s and Children’s Hospital, North Adelaide, Australia
esistance to multiple antimicrobial agents is becom-
ng more frequently seen amongst the Enterobacte-
iaceae world-wide. Much of this is result of the
ccumulation of resistances inside integrons. Thus, resis-
ance to penicillins, beta-lactamase inhibitor combina-
ion, cephalosporins, monobactams, carbapenems, ﬂuo-
oquinolones, aminoglycosides, tetracyclines and folate
ntagonists can be found in various linked combinations
ithin the family. The most problematic species is Kleb-
iella pneumoniae (KPNE), with Escherichia coli (ECOL)
nd Enterobacter species (ENTR) showing rising rates of
ulti-resistance. The increasing rates of linked resis-
ance have created signiﬁcant problems because of limited
reatment choices. Options for treatment of serious infec-
ions caused by extended-spectrum beta-lactamase-(ESBL)-
roducing KPNE and ECOL include carbapenems, considered
he drugs of choice by many, and, only if susceptible, ﬂuoro-
uinolones. Aminoglycosides have not been favoured as the
atients with multi-resistant strains are the most vulner-
ble to the toxic effects. Trimethoprim-sulfamethoxazole,
f tested as susceptible, may be used for minor infections,
ut there is little published experience with its use in seri-
us infections. Tetracyclines are generally not favoured for
nfections caused by Enterobacteriaceae. Carbapenems are
lso favoured for treatment of serious infections caused by
NTR. Again aminoglycosides have been used but have their
ttendant problems, including failure to prevent the emer-
ence of stably-derepressed mutants when used in com-
ination with third-generation cephalosporins. The recent
mergence of carbapenemases in Enterobacteriaceae in
ome parts of the world, especially KPC series enzymes in
PNE and metallo-enzymes in a number of species, have left
ew viable options for treatment. Most experience has been
ained with polymyxins, especially colistin methanosul-
onate. However, doubts about the efﬁcacy of this class
emain, related both pharmacodynamics, and to the poten-
ial for resistance selection. The only readily available alter-
ative is tigecycline, but there is limited experience with
his agent and uncertainty about the adequacy of the cur-
ent dosing regimens. The lack of novel agents active against
ram-negatives in the development pipeline heralds a bleak
uture for treating multi-resistant Enterobacteriaceae.
oi:10.1016/j.ijid.2008.05.143
0.002
arbapenem-resistant Pseudomonas and Acinetobacter
. KamarulzamanUniversity of Malaya, Kuala Lumpur, Malaysia
ver the last decade infections caused by multi drug-
esistant (MDR) gram-negative bacteria have become a
i
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ontinuing and growing problem in both developing and
eveloped nations alike. Nosocomial infections caused by
ram-negative bacteria, particularly Klebsiella spp., E coli,
. aeruginosa, and Acinetobacter spp. have become increas-
ngly difﬁcult to treat due to the rising incidence of drug
esistance and the limited number of antimicrobial agents
hat are effective against them.
Acquired carbapenemases are increasingly reported in
seudomonas and Acinetobacter isolates world wide. The
mergence of these carbapenem-resistant P aeruginosa and
cinetobacter species has provided a particularly difﬁcult
hallenge for clinicians with most carbapenemase produc-
rs being broadly resistant to beta-lactams, and many are
lso resistant to ﬂuoroquinolones and aminoglycosides. Due
o the lack of therapeutic options in these patients who are
ften critically ill, clinicians are often faced with using older
nd more toxic antibiotics such as polymyxins and minocy-
line. Sulbactam which has inherent activity against A
aumannii has also been found to be useful in the treatment
f these infections. Polymyxins are now being commonly
sed to treat these multi drug resistant A baumanii and P
eruginosa with variable success. Additionally, combination
ntimicrobial therapy is frequently employed to treat infec-
ions caused by such multidrug-resistant strains adding to
he potential toxicity and cost of treatment.
Clearly the ever growing threat of the rise MDR gram
egative infections including carbapenem resistant P. aerug-
nosa and Acinetobacter spp cannot be answered by the
evelopment of new antimicrobial agents alone. A multi-
ronged strategy that includes adherence to infection
ontrol principles and antimicrobial stewardship programs
ncluding rational use of current antimicrobial agents must
emain the main stay of the response to this growing health-
are threat.
oi:10.1016/j.ijid.2008.05.144
0.003
eftriaxone-resistant Salmonella
. Gupta
Johns Hopkins University School of Medicine, Baltimore,
D, USA
almonella resistant to extended-spectrum cephalosporins
e.g. ceftriaxone) has become a worldwide problem,
ith over 43 countries reporting cases. These infections
ave been associated with increased risk of bloodstream
nfections, longer duration of hospitalization and pose
treatment challenge, particularly in children. Common
echanisms of this antimicrobial resistance are mediated by
xtended-spectrum beta-lactamases and plasmid-mediated
ephalosporinases, with the CMY-2 being the most widely
isseminated enzyme. In humans, Salmonella enterica
erotypes Typhimurium, Enteriditis and Newport are the
ost common serovars associated with ceftriaxone resis-
ance. The use of antimicrobial agents in livestock,
ncluding cattle, has been associated with the emergence of
ntimicrobial-resistant nontyphoidal Salmonella strains and
ith the dissemination and transmission of these strains to
umans. In this presentation, an overview of the epidemi-
logy, risk factors, antimicrobial resistance mechanisms and
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treatment outcomes of ceftriaxone-resistant Salmonella will
be discussed.
doi:10.1016/j.ijid.2008.05.145
60.004
Fluroquinolone-resistant Gonorrhea
P.R. Hsueh
National Taiwan University Hospital, Taipei, Taiwan
The rapid emergence of ﬂuoroquinolone resistance among
Neisseria gonorrhoeae isolates with a preexisting high preva-
lence of penicillin resistance in the past decade is of
great concern. The prevalence of gonococcal resistance to
ciproﬂoxacin has increased rapidly worldwide in the past
few years, but this increase has varied considerably by
country, ranging from 2.1% in Canada to 86.9% in China.
In Taiwan, ciproﬂoxacin-resistant N. gonorrhoeae was ﬁrst
isolated in 1998. A remarkable increase in the preva-
lence of ciproﬂoxacin resistance was found between 2001
(66.7%) and 2003 (95.2%) at National Taiwan University
Hospital. Previously established guidelines for the manage-
ment of gonorrhea in adults in the United States and the
United Kingdom recommended the use of a ﬂuoroquinolone
(e.g., oﬂoxacin, ciproﬂoxacin, or levoﬂoxacin) as a ﬁrst-
line option for gonorrhea therapy. Failure of gonococcal
infections caused by N. gonorrhoeae strains with resis-
tance to ciproﬂoxacin to respond to treatment with these
agents has been well documented. Accordingly, a ﬂuoro-
quinolone is no longer a ﬁrst-line option for the treatment
of gonorrhea in many countries, particularly those with
high incidence of ﬂuoroquinolone resistance in gonococcal
isolates. Spectinomycin and a cephalosporin (e.g., cefpo-
doxime or ceftriaxone) might be used as the ﬁrst-line agent
for the treatment of gonorrhea, although some gonococcal
isolates exhibiting resistance to the above agents have been
reported.
doi:10.1016/j.ijid.2008.05.146
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Antimicrobial Resistance Among Anaerobes -The
European Experience
C.E. Nord
Karolinska Institute, Karolinska University Hospital,
Stockholm, Sweden
Clinical usage of antimicrobial agents has been accompanied
by the isolation of antimicrobial-resistant bacteria. During
the last years there have been reports showing increas-
ing numbers of anaerobic bacteria resistant to different
antimicrobial agents in Europe. Resistance in anaerobic
bacteria has a signiﬁcant impact on the selection of antimi-
crobial agents for empirical therapy. The development of
antibiotic resistance in anaerobic bacteria has been doc-
umented for beta-lactam drugs, clindamycin, macrolides,
tetracyclines, ﬂuoroquinolones and nitroimidazoles. The
Bacteroides fragilis group is more resistant to antimi-
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robial agents than most other anaerobic bacteria. The
acteroides genus and the genera Prevotella and Por-
hyromonas have become increasingly resistant to many
nti-anaerobic agents. Fusobacterium strains resistant to
eta-lactam drugs are relatively frequent. Resistant anaer-
bic cocci and Propionibacterium acnes have also been
eported. Recently, ﬂuoroquinolone-resistant Clostridium
ifﬁcile strains producing three toxins (toxin A, toxin B and
inary toxin) have been isolated from patients with severe
. difﬁcile diseases.
The resistance mechanisms in anaerobic bacteria are:
) hydrolysis of the antimicrobial drug by several enzymes
efore reaching the site of action (most common, some-
imes plasmid mediated); b) decreased permeability of the
rganisms; c) modiﬁcation at the site of action of the antimi-
robial agent; d) efﬂux mechanisms which eliminate the
ntimicrobial drug from the bacterial cell.
oi:10.1016/j.ijid.2008.05.147
1.002
lostridium difﬁcile Type O27, Coping with a More
irulent Strain
.J. Kuijper1,∗, R. Vonberg2, M. Wilcox3, P. Gastmeier4
Department of Medical Microbiology, Leiden University,
etherlands
Medical School Hannover, Hannover, Germany
Medical Microbiology, Leeds, United Kingdom
Charité University, Berlin, Germany
lostridium difﬁcile (CD) is an anaerobic bacterium capa-
le of forming spores which confer resistance to heating,
rying and chemical agents, including disinfectants. Spores
f CD may survive in the environment for long periods and
re resistant to alcohol. More than 150 PCR ribotypes and 24
oxinotypes have been recognized; epidemic ribotypes may
ave enhanced sporulation. Since 2003, increasing rates of
D infections (CDI) have been reported in North America
nd Europe involving a more severe course, higher mortal-
ty, increased risk of relapse and more complications. The
utbreaks are difﬁcult to control and require a multifaceted
pproach. The most important infection control measures
ct on interruption of transmission of spores to vulnerable
atients from infected patients and from the environ-
ent. Vulnerable patients are mainly patients who receive
ntimicrobial treatment, and therefore fewer antibiotic
rescriptions should lead to less vulnerable patients. At
resent, no sufﬁcient evidence exists to propagate the
se of probiotics to vulnerable patients for prevention
f CDI. Transmission of spores occurs mainly via contact
f contaminated health care workers to patients, directly
y patient-to-patient transmission or by transmission from
he contaminated environment to patients. There is no
irect evidence that patients or healthcare workers who are
ymptom-free but colonised with C. difﬁcile in the intestinal
ract are signiﬁcant sources of infection. Early diagnosis of
DI, prompt isolation of symptomatic patients and reduc-
ng antimicrobial treatment are essential ﬁrst steps. The
nfection control measures include recommendations to iso-
ate infected patient on a single room with designated
oilet, to apply proper hand hygiene with soap and water,
